Electromed, Inc. Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures, and markets SmartVest airway-clearance systems using High Frequency Chest Wall Oscillation therapy. The company serves home-care, institutional, distributor, and international markets. This report covers the quarter and six months ended December 31, 2020, representing fiscal second-quarter and first-half fiscal 2021 results. The financial statements are unaudited.
Financial Performance and Position
| Metric | Three Months Ended Dec. 31, 2020 | Prior Year | Six Months Ended Dec. 31, 2020 | Prior Year |
|---|---|---|---|---|
| Net revenue | $9.496 million | $8.547 million | $17.500 million | $16.849 million |
| Gross profit | $7.525 million | $6.676 million | $13.673 million | $13.018 million |
| Gross margin | 79.2% | 78.1% | 78.1% | 77.3% |
| Operating income | $1.583 million | $1.567 million | $2.246 million | $2.916 million |
| Net income | $1.203 million | $1.185 million | $1.739 million | $2.200 million |
| Diluted EPS | $0.13 | $0.14 | $0.19 | $0.25 |
- Six-month operating cash flow was $1.491 million, compared with $2.024 million in the prior-year period.
- Cash increased to $11.742 million at December 31, 2020 from $10.479 million at June 30, 2020.
- Accounts receivable increased to $15.395 million from $12.941 million, primarily reflecting growth in Medicare-related home-care revenue and its approximately 13-month payment cycle.
- Working capital was approximately $27.410 million. The company reported total liabilities of $3.490 million and shareholders’ equity of $32.334 million.
- Capital expenditures and patent-related spending totaled $143,868 for the six months. No off-balance-sheet arrangements were reported.
- The company had no outstanding borrowings under its $2.5 million revolving credit line; the full amount was available at December 31, 2020. The facility expires December 18, 2021, if not renewed.
Material Changes Versus the Prior Comparable Period
- Total revenue increased 11.1% in the quarter and 3.9% for the six-month period.
- Home-care revenue increased 16.1% for the quarter and 7.9% for the six months, driven by higher referrals and approvals, the CMS Medicare waiver, a hybrid sales model, and more direct sales representatives.
- Institutional revenue declined 37.4% for the quarter and 47.5% for the six months because of COVID-19-related reductions and delays in hospital purchasing.
- International revenue declined 46.6% for the quarter and 31.0% for the six months; distributor purchase timing can create significant quarterly fluctuations.
- Gross margins improved because of a higher mix of home-care revenue and favorable Medicare mix.
- SG&A increased 9.5% for the quarter and 5.9% for the six months, reflecting higher sales incentives, increased sales and marketing staffing, systems investments, and direct-to-consumer marketing. Travel expenses declined because of COVID-19.
- R&D expense increased 254.5% for the quarter and 308.7% for the six months due primarily to next-generation platform development.
- Quarterly net income increased modestly, but six-month net income declined 20.9% because strategic SG&A and R&D investments more than offset revenue growth.
Guidance, Outlook, Risks, and Unusual Items
- Management expects R&D investment to remain in a similar range of approximately 5% to 6% of revenue through fiscal 2021.
- Management believes cash, operating performance, working capital, and available credit will provide adequate liquidity during fiscal 2021.
- The COVID-19 pandemic continued to affect clinic access, referrals, institutional purchasing, operations, and potentially supply chains. Management expects adverse effects to continue during the remainder of fiscal 2021, although home-care referrals improved sequentially in the quarter.
- Temporary CMS waivers relaxed certain Medicare documentation and face-to-face requirements for respiratory products. The waiver was extended for an additional 90-day period beginning January 21, 2021, and management noted that it was expected to remain effective until April 2021. Expiration could affect referrals and approval rates.
- Key risks include changes to Medicare, Medicaid, or private reimbursement; COVID-19 developments; competition; regulatory requirements; international expansion; intellectual-property protection; sales-channel development; and the ability to renew or access credit.
- The credit facility contains financial and nonfinancial covenants, including a minimum tangible net worth of $10.125 million and restrictions on additional indebtedness and dividends. Covenant failure could limit borrowing access or permit acceleration of debt.
- The company maintains a $770,000 warranty reserve and estimates variable consideration for payer appeals, installment arrangements, deductibles, and other reimbursement uncertainties.
- No material undisclosed litigation was identified, and the company reported no unregistered securities sales or defaults upon senior securities.
Important Facts for Investors to Verify
- Whether home-care referral growth and Medicare reimbursement remain durable after CMS waivers expire.
- Whether the increase in accounts receivable converts to cash as expected given the Medicare payment cycle.
- Whether institutional and international revenue recover from pandemic-related weakness.
- Whether elevated R&D, sales, marketing, and systems spending produces sufficient future revenue and margin growth.
- Compliance with the credit facility’s covenants and renewal status before its December 18, 2021 expiration.
- The adequacy of estimates for payer recoveries, doubtful accounts, inventory obsolescence, and warranty claims.